Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes

TY - JOUR

T1 - Resveratrol and inflammation

T2 - challenges in translating pre-clinical findings to improved patient outcomes

AU - Poulsen, Morten Møller

AU - Fjeldborg, Karen

AU - Ornstrup, Marie Juul

AU - Kjær, Thomas Nordstrøm

AU - Nøhr, Mark Klitgaard

AU - Pedersen, Steen Bønløkke

N1 - Copyright © 2015 Elsevier B.V. All rights reserved.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

AB - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

KW - Adipose Tissue/drug effects

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal/pharmacology

KW - Clinical Trials as Topic

KW - Humans

KW - Inflammation/drug therapy

KW - Obesity/drug therapy

KW - Stilbenes/pharmacology

KW - Translational Medical Research

U2 - 10.1016/j.bbadis.2014.12.024

DO - 10.1016/j.bbadis.2014.12.024

M3 - Review

C2 - 25583116

SN - 0925-4439

VL - 1852

SP - 1124

EP - 1136

JO - B B A - Molecular Basis of Disease

JF - B B A - Molecular Basis of Disease

IS - 6

ER -